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Summary Transcranial B-mode sonography (TCS) is a neuroimaging technique that displays the
brain parenchyma and the intracranial ventricular system through the intact skull. Sophisticated
TCS systems can currently achieve a higher image resolution of echogenic deep brain structures
than MRI under clinical conditions. The different imaging principle of TCS allows visualization of
characteristic changes in several neurodegenerative diseases that can hardly be visualized with
other imaging methods, such as substantia nigra hyperechogenicity in Parkinson’s disease (PD),
and lenticular nucleus hyperechogenicity in atypical Parkinsonian syndromes. The intracranial
ventricular system and a midline shift due to space-occupying brain lesions (e.g., intracere-
bral hematomas) are reliably assessed with TCS. The present paper reviews recent studies on
diagnostic TCS applications that, as a result, can be recommended for routine use in clini-
cal practice. These applications include the bedside monitoring of space-occupying lesions in
acute stroke patients, the early and differential diagnosis of PD, and the postoperative position
control of deep brain stimulation electrodes. Novel technologies such as in-time fusion of TCS
with MRI scans, automated detection of intracranial target structures, and improved 3D-image
analysis promise an even wider application of TCS in the coming years.
© 2012 Elsevier GmbH.
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ranscranial B-mode sonography (TCS) is a neuroimaging
echnique that displays the brain parenchyma and the
ntracranial ventricular system through the intact skull. Its
ifferent imaging principle allows visualization of charac-
eristic changes in several neurodegenerative diseases that
an hardly be visualized with other imaging methods, such
s substantia nigra (SN) hyperechogenicity in Parkinson’s
isease (PD) [1,2]. While TCS has been performed in chil-
ren already in the 1980s and 1990s of the last century
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Open access under CC BY-NC-ND license.3,4], the clinical application of TCS in adults has devel-
ped only subsequently since the TCS imaging conditions
re much more difﬁcult in adults because of the thick-
ning of temporal bones with increasing age [5]. In the
990s ﬁrst studies showed that TCS allows the visualiza-
ion of major parenchymal structures, as well as lesions
mainly tumors and bleeding) from the lower brainstem up
o the parietal lobe [6—10], and well reproducible mea-
urements of the whole ventricular system [11]. Due to the
echnological advances of the past decade a high-resolution
maging of deep brain structures is meanwhile possible in
he majority of adults [2,12,13]. Present-day TCS systems
an achieve a higher image resolution in comparison not
nly to former-generation systems, but currently also to MRI
nder clinical conditions (Fig. 1) [13]. A sophisticated clini-
al high-end TCS system was shown to gain an in-plane image
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Figure 1 Comparison of transcranial sonography (TCS) and MRI with respect to image resolution of the network structure of a
kitchen strainer placed within a human skull phantom ﬁlled with ultrasound gel. (A) Photograph of the kitchen strainer consisting
of polyamide threads forming a 1.1mm× 0.8mm network. (B) The transducer (T) was placed at preauricular position for TCS. (C)
Using a contemporary TCS system, the network structure of the intracranially located strainer could be clearly visualized (a = axial
direction, l = lateral direction, 1 = bar indicating ﬁve threads with 1.1mm distance, 2 = bar indicating ﬁve threads with 0.8mm
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adistance). (D) With MRI, simulating clinical conditions, the netw
1.1mm distance) [13].
resolution of intracranial structures in the focal zone of
about 0.7mm× 1.1mm [13]. Beside high image resolution,
contemporary TCS systems also offer high mobility, and TCS
images of good quality are meanwhile obtained with dis-
tinct hand-held TCS systems [14]. Further advantages of
TCS are its non-invasiveness, low costs, high acceptance
by the patients, and relative independence from move-
ment artefacts. This has promoted the development of a
number of clinical TCS applications especially in patients
with movement disorders, and in patients who need bedside
assessment. An important milestone was the establishment
of consensus guidelines on TCS in movement disorders [1],
which was triggered by an activity of the European Soci-
ety of Neurosonology and Cerebral Hemodynamics (ESNCH)
in 2004. The use of ultrasound contrast agents offers an
improved assessment on TCS of patients with acute stroke
[15—17], with brain tumors [18], and inﬂammatory brain dis-
orders [19], but is still on an experimental level and will be
reviewed in another chapter of this serial.
The present paper reviews TCS studies without con-
trast agent application published in the past decade that
assessed novel TCS applications, which can be, as a result,
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structure was not visualized (1 = bar indicating ﬁve threads with
ecommended for clinical use. These applications include
he monitoring of space-occupying lesions in acute stroke
atients, the early and differential diagnosis of PD, and
he postoperative position control of deep brain stimulation
DBS) electrodes.
CS system settings and scanning procedures
or TCS, a contemporary high-end ultrasound system, as
pplied also for transcranial color-coded cerebrovascular
ltrasound, equipped with a 2.0- to 3.5- (1.0- to 5.0-)
Hz transducer can well be used. It has to be considered
hat certain measurements, e.g., of the size of a hyper-
chogenic area are dependent on the applied ultrasound
ystem and the individual system settings. System parame-
ers, such as the width of ultrasonic beam, the line density,
nd even the age of the probe inﬂuence the image resolu-
ion. Therefore, reference values need to be obtained (and
deally updated for the same probe every 2—3 years) sep-
rately for each ultrasound system. The following system
ettings are recommended: penetration depth 14—16 cm,
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Table 1 Ultrasound system settings for transcranial
sonography.
Parameter Settings
Ultrasound system
Penetration depth Start with 14—16 cm, reduce if
needed
Dynamic range 45—55 dB
Postprocessing
function
Moderate suppression of low
echo signals
Time gain
compensation
Adjust manually as needed, or
use the ‘tissue optimization’
function if available
Image brightness Adjust manually, not too high,
or use the ‘tissue optimization’
function if available
Ultrasound transducer
Crystal/channel As high as possible, ideally:
‘matrix’ probe
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Figure 2 Illustration of transcranial sonography (TCS) of
substantia nigra (SN). (A) TCS axial image of the brain at mid-
brain level obtained in a patient with normal appearance of
SN. In the center of the image, the butterﬂy-shaped, weakly
echogenic midbrain is displayed which is surrounded by the
highly echogenic basal cisterns. The rectangle corresponds to
the zoomed image of the midbrain shown in the insert panel in
the right upper corner; in this panel, the echosignals of the
SN are surrounded (here: normal echogenic area). Note the
typical imaging artifact from the basal cistern (arrows) that
should not be mistaken for SN echosignals. For comparison,
an exemplary image obtained in another patient with markedly
hyperechogenic SN is shown in the insert panel in the left upper
corner. (B) Transducer position for TCS. (C) MR image corre-
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tInsonation frequency
(center frequency)
2.0—3.5MHz, preferably
2.5MHz
ynamic range 45—55 dB, and if selectable a post-processing
reset with moderate suppression of low echogenic signals
Table 1). Image brightness and time gain compensation are
dapted visually and/or with using automated image opti-
ization (available with high-end ultrasound systems). For
he examination, the patient is posed in a supine position,
nd the examiner usually sits at the head of the examination
able. The investigation is usually performed through the
ranstemporal bone window consecutively from each side
ith preauricular position of the ultrasound probe (Fig. 2).
ther transcranial approaches used for speciﬁc questions
re the foramen magnum, the transfrontal, and the transoc-
ipital bone window. The latter two, however are more
requently insufﬁcient to insonate in adults. The structures
ssessed at different planes andwindows are detailed below.
here are two standard transtemporal axial scanning planes,
eﬁned by cerebral landmark structures (midbrain, thala-
us), that are recommended to be applied especially at
ny diagnostic examination in patients with movement dis-
rders [1,2], although the course of the examination may
e individually adapted according to the diagnostic question
12,20].
To display the plane at midbrain level, the examination
tarts with the identiﬁcation of the hypo- to anechogenic
utterﬂy-shaped structure of mesencephalic brainstem sur-
ounded by the highly echogenic basal cisterns in the axial
canning plane. The mesencephalic brainstem surrounded by
he highly echogenic basal cisterns can easily be delineated
n 90—95% of individuals, even in those with only partially
ufﬁcient acoustic bone windows. Within the brainstem, sev-
ral structures of increased echogenicity, including SN, red
ucleus, the midline raphe, and the aqueduct can be visual-
zed. For the clinical applications described in this article,
he assessment of SN echogenicity is most important. To
ate, the best-validated method to grade SN echogenicity
s the planimetric measurement of SNs echogenic signals
n axial plane [1,2,20]. Semiquantitative visual grading was
ess reliable [20,21]. Efforts to quantify SN echogenicity in
m
i
m
mponding to the TCS plane shown in (A).
less rater-dependent way, e.g., by measuring echointen-
ity of SN relative to surrounding parenchyma, volumetry,
emi-automatic SN detection, or complex mathematical
cho-signal analysis have either failed, or are not ripe for
linical application [20]. According to consensus guidelines
1], a marked SN hyperechogenicity is considered, if the
easured echogenic area exceeds a cut-off value deﬁned by
he 90% percentile of measures in normal population, and
oderate hyperechogenicity, if the measured area ranges
n-between the 75% and 90% percentile of measures in nor-
al population. Most authors use the larger of bilaterally
easured sizes for rating SN echogenicity.
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Table 2 Reported cut-off values for the discrimination between normoechogenic and hyperechogenic substantia nigra with
different ultrasound systems.
Manufacturer/ultrasound system Probe/frequency (MHz) Cut-off value (cm2) SN-h References
Esaote/AU4 Phased-array/2.5 ≥0.20 [23]
Esaote/MyLab25 Gold PA240/2.5 ≥0.20 [14]
Esaote/MyLab Twice PA240/2.5 ≥0.24 (Own data)
Esaote/Technos MP Sector/2.5 ≥0.19 [26]
General Electric/Logiq 7 3S/2.5 ≥0.24 [24]
General Electric/Logiq 9 3S/2.5 ≥0.20 [28]
Philips/HP Sonos 4500 S3/2.25 ≥0.20 [25]
Philips/HP Sonos 5500 Adult cardiac/1.8—3.6 ≥0.20 [27]
Siemens/Acuson Antares PX4-1/2.5 ≥0.24 [21]
Siemens/Sonoline Elegra 2.5PL20/2.6 ≥0.20 [22]
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vAbbreviations: SN-h, substantia nigra hyperechogenicity.
Hitherto, standard reference values on echogenic sizes
of the SN have been published for a number of ultrasound
systems as listed in Table 2 [14,21—28].
To display the plane at thalamus level the ultrasound
probe is tilted 10—20◦ in upward direction. An important
landmark of the thalamus level is the usually calciﬁed, and
therefore highly echogenic pineal gland (Fig. 3). At this
plane, the third ventricle, anterior horns of the lateral
ventricles, the thalami and the anatomic site of the basal
ganglia are depicted. The thalami are typically displayed as
hypoechogenic oval structures; the thalami and the frontal
horns help to discern the anatomical site of caudate nucleus
and lenticular nucleus. At this level, the transverse diam-
eters of the third ventricle, and of the frontal horn of
the contralateral lateral ventricle can be measured [1,11].
Hydrocephalus can be easily diagnosed on TCS. In addi-
tion, early brain atrophy and associated risk of cognitive
impairment can be detected with TCS by measurement of
third-ventricle width [29]. Furthermore, the echogenicity
of contralateral thalamus, contralateral lenticular nucleus
and contralateral caudate nucleus should be evaluated semi-
quantitatively. Normally, these structures are invisible, i.e.,
a
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Figure 3 Transcranial sonography (TCS) axial brain scan at
Th = thalamus; 3 = third ventricle (width indicated by bar); *frontal
indicated by bar); triangle indicates pineal gland. (A) MRI scan corr
scan through the brain at thalamus level of an individual with nor
(triangle) is normal since this structure usually contains chalk. The
(arrow). (C) TCS axial scan through the brain at thalamus level of a su
atrophy). The increased echogenicity (‘hyperechogenicity’) of the lesoechogenic to the surrounding brain parenchyma. Some-
imes, the borders of the ipsilateral internal capsule can
e detected, allowing a separation of the thalamus from
he lenticular nucleus. An increased echogenicity (‘hyper-
chogenicity’) of thalamus, lenticular nucleus or caudate
ucleus compared with surrounding white matter is con-
idered to be abnormal. Hyperechogenicity of deep brain
tructures is often caused by trace metal accumulation or
y calciﬁcation [2]. In the latter case, the echosignals are
ery bright, similar to that of pineal gland [30].
CS for monitoring of acute stroke patients
wo of the earliest published TCS applications in adults were
he detection of intracranial hematomas in acute stroke
r trauma patients [8,10,31], and the assessment of the
entricular system [11]. While computed tomography (CT)
nd MRI today represent the gold standard in the diag-
osis of intracranial hemorrhage [32,33], TCS can well be
sed for the bedside monitoring for the size and resorp-
ion of hematomas, and, especially for the monitoring of
thalamus level. C = caudate nucleus, L = lenticular nucleus,
horn of lateral ventricle (width of contralateral frontal horn
esponding to the TCS images shown in (B and C). (B) TCS axial
mal TCS ﬁndings. The increased echogenicity of pineal gland
lenticular nucleus is displayed with low (normal) echogenicity
bject with an atypical Parkinsonian syndrome (multiple-system
nticular nucleus (arrow) is a characteristic ﬁnding.
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Figure 4 Transcranial sonography (TCS) axial brain scan at thalamus level showing a large intracerebral hematoma. (A) Computed
tomography (CT) image corresponding to the TCS image shown in (B). The triangles indicate the hematoma. (B) TCS image showing
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dhe highly echogenic hematoma in the acute phase. The midlin
he distance d of the temporally placed transducer face to the
hift = (d1−d2)/2.
idline shift. In the acute phase, intracerebral hemorrhage
ICH) appears homogenous, sharply demarcated and hyper-
chogenic (Fig. 4) [31]. In 1993, Seidel et al. [8] were the
rst to describe an alteration of the sonographic appearance
f ICH over time with a decrease in echo intensity begin-
ing at the center of the lesion. They were able to detect
he ICH with ultrasound in 18 of 23 patients (78%). Insufﬁ-
ient insonation conditions were found in 13% of patients.
n a prospective TCS study of 151 patients with acute hemi-
aresis of whom 60 had an ICH on CT, TCS differentiated
orrectly between ischemia and hemorrhage in 95% of the
ssessable patients [34]. Insufﬁcient insonation conditions
ere found in 12% of patients. In a more recent study of 25
atients with conﬁrmed subdural hematoma, TCS detected
he hematoma in 22 (88%) patients while the temporal bone
indow was insufﬁcient in 3 (12%) patients [35]. Large hem-
rrhagic transformations of ischemic infarctions have also
een reliably detected with TCS [36,37]. A recent study
ound a good agreement between TCS and CT measures of
ematoma volumes [38].
The ﬁrst TCS studies that speciﬁcally addressed the value
f TCS in the evaluation of midline shift in patients with
pace-occupying brain infarctions were published by the
roup of Kaps and co-workers [39—41]. In these studies a
igh correlation between TCS and CT measures of midline
hift at the level of third ventricle was found. All patients
ith an MLS < 4mm at 32 h survived, whereas patients with
n MLS > 4mm died, as a result of cerebral herniation with
n exception of one patient who underwent decompressive
emicraniectomy [40,41]. Subsequent studies performed by
ndependent groups conﬁrmed the reliability of TCS in the
ssessment of midline shift in patients with space-occupying
troke, ICH and traumatic brain injury [42—45]. In a recent
tudy, the widths of lateral ventricles (frontal horns) were
onitored with TCS in 37 patients with intraventricular
emorrhage [46]. The authors reported a cut-off value for
ncrease of lateral ventricular width of 5.5mm that yielded
igh sensitivity (100%) and speciﬁcity (83%) in combination
ith a 100% negative predictive value for reopening of the
xternal ventricular or lumbar drainage.
In conclusion, TCS can be regarded as a reliable tool
or monitoring the midline shift, as well as the ventricular
i
h
S
aft at level of third ventricle can be calculated after measuring
ventricle (indicated by double arrow) from both sides: midline
idth in patients with acute supratentorial brain lesions who
ave adequate acoustic bone windows (>80% of patients).
n many neurological and neurosurgical departments with
ppropriate expertise in neurosonology, TCS is already today
outinely used for this purpose.
CS for the early and differential diagnosis of
arkinson’s disease
ubstantia nigra hyperechogenicity in Parkinson’s
isease
ecker et al. [47] were the ﬁrst to describe the TCS ﬁnd-
ng of SN hyperechogenicity in PD patients (Fig. 2). In the
ast decade, this ﬁnding has been conﬁrmed by a number
f independent groups [23—25,27,28,48—54]. This TCS ﬁnd-
ng, present in about 90% of PD patients at cross-section
s independent from PD duration and severity [55,56],
nd was found to be stable in a 5-year follow-up study
f PD patients [57]. Also there was no correlation found
etween the degree of SN hyperechogenicity and the stri-
tal uptake of N-omega-ﬂuoropropyl-2beta-carbomethoxy-
beta-4-[(123)I]iodophenyl-nortropane (FP-CIT) on SPECT,
hich is thought to represent a correlate for the degenera-
ion of presynaptic dopaminergic neurons in PD [58]. These
ndings indicate that SN hyperechogenicity is not a correlate
f the progressive degeneration of SN neurons.
However, a close correlation between SN echogenicity
nd tissue iron content has been shown in post-mortem
tudies of human brains [59], suggesting that SN hypere-
hogenicity in PD is at least in part, caused by an elevated
ron content of the SN. Also in a number of other neu-
odegenerative disorders TCS was demonstrated to detect
ccumulation of trace metals (iron, copper, manganese) in
he basal ganglia with higher sensitivity than MRI supporting
he idea that TCS can display trace metal accumulation in
eep brain structures [59—62]. On the other hand, increased
ron content alone cannot be the only explanation for SN
yperechogenicity since iron accumulates over time in the
N of PD patients, and other iron-rich brain structures, such
s red nucleus or globus pallidus internus normally show
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no increased echogenicity on TCS [2]. Therefore, additional
factors, such as abnormal iron—protein bindings were pro-
posed to contribute to SN hyperechogenicity [59]. The close
correlation of the TCS ﬁnding of SN hyperechogenicity with
increased iron content in the SN [59], together with an
apparently autosomal dominant inheritance of this echofea-
ture in relatives of patients with idiopathic PD [63], supports
the idea of a primary role of disturbed iron metabolism
in PD. Subsequent mutation analyses of genes encoding
for iron-transport and iron-regulatory proteins known to be
associated with Parkinsonism led to the discovery of spe-
ciﬁc mutations in the ferritin-H, the iron-regulatory protein
2, and the hemochromatosis gene, respectively, in single
PD patients with SN hyperechogenicity [64—66]. The most
striking association was found in the ceruloplasmin gene: of
ﬁve exonic missense mutations, the I63T mutation was only
found in one PD patient, the D544E and R793H mutations
in far more PD patients than in ethnically matched con-
trols [67]. The ceruloplasmin gene mutations were clearly
associated to the TCS ﬁnding of SN hyperechogenicity in PD
patients and healthy control subjects [67].
Early diagnosis of Parkinson’s disease
The question of whether the TCS ﬁnding of SN hypere-
chogenicity, present in 90% of PD patients but also in 9%
of healthy adults, really indicates an increased risk of later
developing PD is currently being studied in large longitu-
dinal studies. First clues were reported by Becker et al.
[47] who observed that one of the healthy subjects in whom
marked SN hyperechogenicity was detected in an early TCS
study, two years later developed PD [22]. Meanwhile, there
is growing evidence supporting the idea that SN hypere-
chogenicity indeed is an indicator for an increased risk of
PD. FDOPA-PET studies in young healthy adults as well as in
young asymptomatic parkin mutation carriers revealed that
SN hyperechogenicity is associated with a subclinical mal-
function of the nigrostriatal dopaminergic system [22,68].
In psychiatric patients the degree of SN hyperechogenic-
ity was clearly correlated with the severity of Parkinsonian
symptoms induced by neuroleptic therapy [69]. SN hyper-
echogenicity was related to subtle motor asymmetry in
non-depressive and, even more frequently, in depressive
subjects [70,71]. TCS studies in populations known to have
an increased risk of PD showed 2- to 4-fold increased fre-
quencies of SN hyperechogenicity in ﬁrst-degree relatives
of PD patients [63], in individuals with idiopathic hypos-
mia [72], in patients with unipolar depressive disorders
[73], individuals with essential tremor [24], and individ-
uals with idiopathic REM sleep behavior disorder [74,75].
In these groups, the subjects with SN hyperechogenicity
were more liable to show subtle Parkinsonian motor signs
and reduced striatal radiotracer uptake on FP-CIT SPECT or
F-DOPA PET studies than subjects with normal SN echogenic-
ity [63,71—75]. Recently, the ﬁrst follow-up data came out
of an ongoing longitudinal study since 2004, conducted at
the Universities of Tübingen (Germany), Innsbruck (Austria)
and Homburg (Germany) [76,77]. This study included more
than 1800 healthy individuals older than 50 years who were
examined with respect to SN echogenicity and epidemio-
logic risk factors, as well as premotor symptoms of PD like
P
(
t
i339
epression, autonomic and smelling dysfunction, neuropsy-
hological deﬁcits and slight motor signs. The 37-months
rospective follow-up data obtained in this cohort suggest a
7-fold increased risk of subsequently developing PD in indi-
iduals with SN hyperechogenicity. A prospective follow-up
tudy of individuals with idiopathic REM sleep behavior dis-
rder showed an 100% sensitivity and a 55% speciﬁcity of
ombined 123I-FP-CIT SPECT and TCS to predict the conver-
ion to a synucleinopathy (mainly PD) after 2.5 years [78].
It appears reasonable to combine TCS with other, ide-
lly non-invasive, methods to enhance the predictive value
n the early diagnosis of PD. In a prospective study we
ave assessed more than 500 patients with early parkin-
onism (PD, vascular parkinsonism, atypical parkinsonian
yndromes, essential tremor, major depressive disorder with
otor slowing) on the Uniﬁed PD Rating Scale for motor
symmetry, on the 12-item Snifﬁn’ Sticks test for hyposmia,
nd on TCS for SN hyperechogenicity. Results of this study
howed that the combination of these measures markedly
mproves the prediction of PD, with a speciﬁcity of nearly
00% if all three key ﬁndings were present [79].
The combined assessment of motor asymmetry, hyposmia
nd SN hyperechogenicity could be used as a cost-effective
ool for the screening of populations at risk of developing
D. This assessment battery is applicable in an ambulatory
etting using the Snifﬁn’ Sticks test or similar tests, and
portable TCS system [14]. Subjects assessed to have an
ncreased liability of developing PD, as well as subjects with
igns of mild Parkinsonism, but still an unclear diagnose,
ight be included in a follow-up program at specialized
enters [80]. Such a program might offer further diagnos-
ic steps, including elaborate motor and neuropsychological
nalysis, advanced structural and functional brain imaging,
nd genetic testing. Even though the ethical issues of such
n approach need to be resolved, the early correct diagno-
is of PD promises enhanced success of disease-modifying
herapies.
ifferential diagnosis of Parkinson’s disease
he TCS feature of SN hyperechogenicity, which is a charac-
eristic for PD is usually not found in patients with atypical
r secondary Parkinsonian disorders such as multiple-
ystem atrophy (MSA) and progressive supranuclear palsy
PSP) [50,81—84], posttraumatic Parkinsonism [85], vas-
ular Parkinsonism [86], and welding-related, supposedly
anganese-induced Parkinsonism [62]. According to a meta-
nalysis of ﬁve independent TCS studies [50,81—84], the
nding of SN hyperechogenicity discriminates PD from atyp-
cal Parkinsonian syndromes (MSA and PSP) with a sensitivity
f 92% and a speciﬁcity of 80% [2]. On the other hand, hyper-
chogenic lesions of the lenticular nucleus can be typically
een on TCS in primary degenerative atypical Parkinsonian
isorders but rarely in PD [62,81—83] (Fig. 3). While TCS
f SN alone is helpful for discriminating a number of atypi-
al Parkinsonian syndromes from PD already at early disease
tages [81,84], the speciﬁcity for the diagnosis of MSA and
SP can be increased to 98—100% at the cost of sensitivity
65—84%) by combining TCS of SN, lenticular nucleus and
hird ventricle [82,83], or by combining SN TCS with test-
ng for hyposmia and motor asymmetry [79]. Since clinical
340 U. Walter
Figure 5 Post-operative transcranial sonography (TCS) of a patient with deep brain stimulation (DBS) in whom unilateral DBS lead
displacement was diagnosed. The lead dislocation on the right side was ﬁrst detected on TCS and subsequently conﬁrmed on CT. (A)
TCS image showing the left-sided DBS lead tip (arrow) correctly located within the subthalamic nucleus while the right-sided DBS
electrode is not displayed due to dislocation. (B) TCS image showing the more cranial parts of the left-sided DBS lead (arrow) and
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yhe tip of the dislocated right-sided lead (arrow) lateral from th
A). (D) CT image corresponding to the TCS image in (B).
nd other neuroimaging methods often do not allow a clear
ifferentiation of atypical Parkinsonian syndromes versus PD
n the early disease stages, TCS is a valuable tool for early
iagnosis, and may promote a sooner initiation of disease
peciﬁc therapies.
CS for post-operative localization of brain
mplants
n patients with DBS, there are discrepancies of up to
mm (average 2mm) between the initial selected target
nd the ﬁnal DBS lead location caused mainly by caudal
rain shift that occurs once the cranium is open [87]. More-
ver, the DBS lead may get displaced postoperatively, e.g.,
y delayed brain shift or head injury. Provided sufﬁcient
maging conditions (sufﬁcient bone window, contemporary
igh-end ultrasound system), TCS is a valuable tool for the
ost-operative monitoring of the DBS electrode location
88,89]. Gross DBS lead dislocation is easily detected with
CS (Fig. 5). A detailed overview and recommendations on
Rudate nucleus. (C) CT image corresponding to the TCS image in
he application of TCS for the post-operative localization of
BS electrodes are given in chapter XX3 of this serial.
onclusions and outlook
n the past decade, the technological advances realized in
he commercially available ultrasound systems went along
ith an enormous progress in the application of TCS in
atients with brain disorders. The present article focused
n the clinically most relevant applications of TCS that
re supported each by the results of prospective studies.
ovel technologies, such as the in-time fusion of TCS with
RI images [90], automated detection of intracranial tar-
et structures [91], and improved 3D-image analysis [92]
romise an even wider application of TCS in the coming
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